anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
For patients in arm pemetrexed/carboplatin, folic acid (350-1000 μg) must be given daily beginning approximately 5-7 days prior to first dose of pemetrexed and continuing daily until 3 weeks after the last dose of study therapy. Vitamin B12 (1000 μg) will be administered as an intramuscular injection approximately 1 to 2 weeks prior to first dose of pemetrexed and repeated approximately every 9 weeks until 3 weeks after the last dose of study therapy. Dexamethasone (4 mg of oral or equivalent) given twice daily should be taken on the day before, the day of, and the day after each dose of pemetrexed, for rash prophylaxis unless medically contraindicated. Patients must receive pemetrexed at day 1 at the dose of 500 mg/m2 as an IV infusion over approximately 10 minutes, then carboplatin target area under the concentration curve (AUC) 6 (i.v. infusion over 30 minutes) on day 1 of a 21-day cycle. A total of four cycles is intended.
This study will be carried out at the Hysteroscopy center of the Fuxing Hospital, Beijing, China. At least 82 recurrent miscarriage women with a diagnosis of arcuate uterus who had unexplained recurrent spontaneous abortion (less than 12 weeks) before and have fertility requirement will be recruited. The patients will be explained the study and sign the informed consent. According to the random number table, the corresponding cases were divided into treatment group and control group. The experimental group will be given hysteroscopic treatment, the control group will receive no treatment. The follow up of the spontaneous abortion rate and the pregnancy rate of two groups will be screened within 1-2 years and the correlation between the arcuate uterus and recurrent miscarriage will be analyzed.
(A) N-(Lower alkyl)-neoalkanamides in which the alkyl residue contains 1-4C atoms and the neoalkanoyl group contains 7-14C atoms are new. (B) New washing agents for hard or soft surfaces in order to render them insect repellent comprise a soap or an organic synthetic wash-active substance in an amount sufficient to exert a cleaning action and an insect-repellent amount of an N-(lower alkyl)- neoalkanamide as defined above. (C) New insect repellent solid cleansing agents in bar form contain soaps and/or surface active agents and insect repellent amounts of N-alkyl-neoalkanamides in which the alkyl group contains 18C atoms and the neoalkanoyl group contains 7-14C atoms. (D) New insect repellent compsns. contain alkyl-neoalkanamides in which the alkyl residue contains 1-18C atoms and the neoalkanoyl residue contains 7-14C atoms dispersed or dissolved in a liq. medium. (E) In a new procedure for rendering an area as goods insect repellent, N-(1-18C alkyl)-(7-14C neoalkanamides) are applied to the area or goods or their vicinity. (F) New perfumes contain one or more N-(1-4C alkyl)-(5-14C neoalkanamides) and at least one perfume component selected from essential oils, esters, ethers, aldehydes, alcohols, hydrocarbons, ketones and lactones, the N-alkyl-neoalkanamide concn. being 0.1-98wt.%.
PURPOSE:To obtain the titled antiulcer agent, containing a water soluble fraction extracted from leaves of Fatsia japonica (Japan fatzia) and having high safety. CONSTITUTION:An antipeptic ulcer agent obtained by finely cutting leaves of Fatsia japonica (Japan fatzia), drying the cut leaves, adding an alcohol, such as methanol, stirring the mixture, carrying out extraction at 10-80 deg.C to provide an extract, suspending the above-mentioned extract in water, adding an alcohol sparingly soluble in water (e.g. n-butanol), distributing and extracting the resultant aqueous layer and concentrating the obtained aqueous layer to afford an active ingredient thereof having the following properties. Solubility: Readily soluble in methanol and sparingly soluble in ethyl ether, chloroform, benzene and ethyl acetate. Total nitrogen content: <=1.0wt.%. Color reaction: Positive to phenol-sulfuric acid reaction, resorcin-sulfuric acid reaction and anthrone-sulfuric acid reaction. pH: pH 4.2-4.8 of a solution prepared by dissolv ing 1g active ingredient in 10ml water. An oral agent, such as powder, capsule and solution are preferred as the dosage form. The does thereof is preferably 1,000mg/kg/day administered in about 3 divided portions a day.
FIELD: pharmacy. SUBSTANCE: composition containing an active substance is applied with ethylcellulose an aqueous dispersion that comprises as a plasticizer at least one physiologically acceptable lipophilic diester of aliphatic or aromatic dibasic C 6 -C 40 -carboxylic acid and aliphatic C 1 -C 8 -alcohol. Drying is carried out during applying the coating under usual for this process temperatures. If necessary for increase the rate release of active substance and without deterioration of ability of composition to retain its properties in storage this composition is subjected for thermostatic control at temperature >35 C. Invention provides realization of indicated designation. EFFECT: valuable properties of compositions. 14 cl, 11 dwg, 5 ex
Daily 15-min yoga sessions at home during 12 weeks. One 90-min yoga-therapeutic education session/week (during 6 weeks).
The myocardium is a highly oxidative tissue in which mitochondria are essential to supply the energy required to maintain pump function. When pathological hypertrophy develops, energy consumption augments and jeopardizes mitochondrial capacity. We explored the cardiac consequences of chronic swimming training, focusing on the mitochondrial network, in spontaneously hypertensive rats (SHR). Male adult SHR were randomized to sedentary or trained (T: 8-week swimming protocol). Blood pressure and echocardiograms were recorded, and hearts were removed at the end of the training period to perform molecular, imaging, or isolated mitochondria studies. Swimming improved cardiac midventricular shortening and decreased the pathological hypertrophic marker atrial natriuretic peptide. Oxidative stress was reduced, and even more interesting, mitochondrial spatial distribution, dynamics, function, and ATP were significantly improved in the myocardium of T rats. In the signaling pathway triggered by training, we detected an increase in the phosphorylation level of both AKT and glycogen synthase kinase-3 β, key downstream targets of insulin-like growth factor 1 signaling that are crucially involved in mitochondria biogenesis and integrity. Aerobic exercise training emerges as an effective approach to improve pathological cardiac hypertrophy and bioenergetics in hypertension-induced cardiac hypertrophy.
Qualifying participants will begin combination therapy with ambrisentan pill 5 mg daily and tadalafil pill 20 mg. After one week of therapy, patients will increase tadalafil pill to 40 mg daily and continue ambrisentan pill 5 mg daily. On day 15, patients will increase ambrisentan pill to 10 mg daily and continue at 40 mg of tadalafil pill daily.
BACKGROUND: The NFLymSI-18 is a patient-reported outcome measure comprised of the highest priority symptoms, emotional concerns, treatment side effects, and other concerns identified by lymphoma patients and oncologists. This study assessed the content validity of the NFLymSI-18 for patients with indolent B-cell non-Hodgkin's lymphoma (iNHL), with a focus on the Disease-Related Symptoms Physical (DRS-P) subscale.
METHODS: Patients with a confirmed iNHL diagnosis who had received one or more lines of treatment were recruited during clinic visits. Patients described their symptoms, treatment side effects, and emotional concerns related to iNHL in a semi-structured interview. Qualitative data were analyzed using NVivo10.
RESULTS: Data saturation was obtained by the 18th interview. Most participants (67%) had follicular lymphoma. 28% of participants had marginal zone lymphoma, and one participant had lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia. Mean age of the 18 participants was 67 years. 56% of the sample was male. Most participants (67%) had a college or advanced degree. When asked to describe their iNHL symptoms, patients most often discussed swelling (n = 14), fatigue (n = 11), and pain (n = 8). The following symptoms were mentioned by three patients each: anxiety, appetite loss, rash, sleep disruption, trouble breathing, and malaise. Mapping of NFLymSI-18 content to these concerns showed the instrument includes all those most frequently mentioned symptoms.
CONCLUSIONS: This study supports the content validity of the NFLymSI-18, including its DRS-P Subscale, for patients with iNHL. The instrument shows strong validity for the most referenced symptoms of swelling, fatigue, and pain. The diversity of additional symptoms reported by patients is consistent with the heterogeneous symptomology of iNHL.
Sleep disorders present significant challenges to public health, necessitating effective and sustainable solutions beyond conventional pharmacological interventions. This study aims to investigate the potential of honey and its compositions as a functional food for addressing sleep disorders. A comprehensive review of existing literature explores honey's intrinsic properties and impact on sleep quality. The findings suggest that honey, with its unique composition and soothing effects, offers a promising avenue for enhancing sleep patterns without relying on pharmaceutical drugs. This study also discusses the possible mechanism of action and the challenges of using honey in this field. While further research is needed to elucidate specific mechanisms and optimal utilisation, integrating honey into holistic sleep management strategies holds promise for improving overall well-being and quality of life.
There will be 140 participants in this study who will be randomly allocated into either intervention group (70) or control group (70).The intervention group will receive one hour long "Safeguard Your Smile" intervention and control group will receive no intervention and only a conventional pamphlet. Data will be collected at baseline and after 3 months using three research instruments. i) Oral hygiene self-care knowledge and oral hygiene self-care behavior will be assessed using self administered questionnaire. ii) Using Loe and Sillness indices, plaque and gingival index scores will be measured. iii) And oral health literacy of participants will be measured with the TS-REALD tool.The data analysis will include descriptive statistics and frequency tables will be provided for both baseline and endpoint data of the both groups. Continuous variables will be summarized with mean, standard deviation and range and for the categorical variables; frequency counts and percentage of subjects within each category will be provided. An array of data analysis including t-test, correlations and logistic regression will be performed assessing effectiveness of the Safeguard Your Smile intervention.
An apparatus for graphically displaying analytical data, comprising a generic model to graphically represent a complex set of physical characteristics potentially leading to catastrophic failure of a physical system. A central region represents failure of the physical system; a series of concentric ridges represents level of function. Wedge shaped regions upon the ridges represent predetermined subsystems of the physical system. An icon is displayed with changes in the icon proportional to time, and any one or more of color, position, shape, and rotation of the icon representing prescribed analysis of the physical characteristics. Mappings correlate predetermined characteristics of the system with failure of the physical system, levels of functioning represented by the ridges, subsystems represented by the wedge shaped regions, and/or analysis of the physical characteristics represented in the icon. A sensor interface receives measurements, and a graphics generator prepares a presentation of the model.
The mother's upper clothes were removed by the researcher. With the palms of the hand the breast grasped from the bottom and top. The hands were advanced by pressing slowly from the base of the nipple towards the nipple. With the palms, the breast was grasped from the bottom and top and gently pressed. Using fingertips, the breast was scanned by massaging from the base of the nipple to the nipple in circular movements. The mothers received breast massage four times over the course of 24 hours.
Only a few studies have investigated olfactory function in patients with obstructive sleep apnea syndrome (OSAS) using psychophysical testing, and there is a scarcity of data regarding taste evaluation in the existing literature. The primary objectives of this study were to assess both smell and taste in patients with OSAS and to explore the correlation between the severity of symptoms and sensory perception. A total of 85 OSAS patients and a control group comprising 81 subjects were enrolled. Initial assessments included anamnesis, nasal endoscopy, and the completion of questionnaires (Epworth Sleepiness Scale, Visual Analogue Scale, Questionnaire of Olfactory Disorders, and the importance of olfaction questionnaire). The diagnosis of OSAS was confirmed by polysomnography, while nasal airflow was evaluated using rhinomanometry. Olfaction was assessed using the Sniffin' Sticks test, and the Threshold-Discrimination-Identification (TDI) score was calculated. Taste evaluation was conducted in a subgroup of participants (42 patients, 38 controls) using taste strips. The mean TDI score was 31 ± 5.6 for OSAS patients and 35 ± 4.6 for controls, indicating a significant difference (P < 0.001). Similarly, the taste score was 7 ± 3.0 for OSAS patients and 12.6 ± 3.2 for controls (P < 0.001). No correlations were observed between TDI and Apnea Hypopnea Index (AHI) (r = -0.12; P = 0.28), as well as between the taste score and AHI (r = -0.31; P = 0.22). However, a weak but significant correlation between TDI score and Epworth Sleepiness Scale was detected (r = -0.05; P = 0.002). The study revealed a significant decrease in sensory perception among patients with OSAS, though open questions persist about the pathophysiology.
INTRODUCTION: Postoperative fracture site infection can lead to notable patient morbidity, increase cost of care, and further contribute to healthcare disparities globally. Dogma suggests surgical blades as a vehicle for introducing bacteria into the surgical site; however, there is a paucity of literature to support this claim. This study uses advanced DNA sequencing to detect bacterial DNA on surgical blades used in upper extremity fracture surgeries.
METHODS: This was a prospective study, conducted at a high-volume level 1 trauma center. All acute, closed upper extremity fractures requiring surgical stabilization were consecutively enrolled in a prospective fashion. The primary end point was the presence of bacterial DNA on the surgical blade using next-generation sequencing (NGS). At the time of surgery, two blades were sterilely opened. One blade served as the control while the other was used for the initial skin incision. Two negative control blades were opened directly into a sterile container. Two positive control blades were used for skin incision through known infections. All samples were sent for NGS analysis.
RESULTS: Forty patients were enrolled in this study. The median age was 33.5 years, and 30% were female; the median body mass index was 26.52. Humerus fractures were the most common injury (N = 17, 42.5%), followed by clavicle fractures (13, 32.5%) and radius/ulna fractures (10, 25.0%). NGS analysis revealed no contamination of test blades used for skin incision. Three control blades tested positive for bacterial DNA. Negative control blades tested negative for bacterial DNA (0/2); the positive control blades resulted positive for bacterial DNA contamination (2/2).
CONCLUSION: Surgical blades used for skin incision in the upper extremity are not contaminated with bacterial DNA as analyzed by NGS. This finding challenges previous surgical dogma regarding surgical blade contamination and supports that the same surgical blade can safely be used for deeper dissection.
LEVEL OF EVIDENCE: Level II study: IRB approval-IRB#848938.
Delayed onset muscle soreness (DOMS) represents a phenomenon characterised by a range of symptoms, encompassing varying degrees of muscle stiffness and pain, from mild to severe, with the potential to cause considerable functional impairment. This may be attributed to muscle damage and subsequent inflammation resulting from eccentric contractions or activities of an unusually intense nature. In accordance with these principles, exercise-induced DOMS typically manifests following an abrupt increase in exercise intensity, the execution of unconventional exercise movements, and most notably, following the performance of exercises that necessitate eccentric muscle actions . DOMS frequently results in a reduction in muscle function, including a decline in strength, a narrowing of the range of motion, increased pain sensitivity, and a decrease in the intensity of proprioception sensations within a period of 24 to 72 hours, with the potential for these effects to persist for several days. The processes underlying of DOMS comprise overstretching of sarcomeres, mechanical stresses in muscle structures, overlaps and disruption of filaments, and reactions of biochemical that affect contractile structures of muscle. Furthermore, inflammatory processes linked to oxidative stress and an increased pain receptors sensitivity is additional factors contributing to the development of DOMS .

One of the most significant factors affecting pain is sleep. Those suffering from persistent pain consistently indicate inferior sleep quality in comparison to controls , and a direct correlation has been observed between the quality of sleep and the severity of pain experienced by individuals. It is established in the literature that the sensitisation of pain mechanisms is raised in both intervention models of acute pain and chronic pain. Furthermore, individuals who experience primary insomnia without pain report heightened sensitivity to pain and an increased frequency of spontaneous pain episodes compared to control subjects. The findings of experimental studies indicate that sleep disruption in healthy individuals is linked to a considerable rise in pain sensitivity, potentially associated with elevated serum concentrations of pro-inflammatory biomarkers, even in the absence of tissue damage. This results in a vicious cycle of pain and sleep disorders, with each condition precipitating the other, thereby rendering the problem challenging to comprehend.
PURPOSE:To obtain interleukin 1, by separating a particular cell from the lymphocyte of human leukemia patient, and culturing the cell in the presence of concanavalin A and forbolmyristate acetic acid ester. CONSTITUTION:An interleukin-producing cell is prepared by culturing and lining the lymphocyte tumor cell collected from an abnormal leukemia patient. The cell is cultured in the presence of concanavalin A and phorbolmyristate acetic acid ester or phytohaemaglutinin to obtain interleukin 1. The obtained interleukin 1 can be converted to interleukin 2 by culturing Jurcut cell in the presence of the interleukin 1. The lined cell exhibits remarkable interleukin 1-producing activity. The interleukin 1 is a T-cell-activating soluble factor, and the interleukin 2 is a soluble factor originated from lymphocyte. The latter is useful as a remedy for cancer, and the former is useful as an agent to promote the production of the latter substance.
Treatment of Duodenal Ulcers

Famotidine 20 mg p.o. h.s., was compared to placebo h.s. as maintenance therapy in two double-blind, multicenter studies of patients with endoscopically confirmed healed duodenal ulcers. In the U.S. study the observed ulcer incidence within 12 months in patients treated with placebo was 2.4 times greater than in the patients treated with famotidine. The 89 patients treated with famotidine had a cumulative observed ulcer incidence of 23.4% compared to an observed ulcer incidence of 56.6% in the 89 patients receiving placebo (p<0.01). These results were confirmed in an international study where the cumulative observed ulcer incidence within 12 months in the 307 patients treated with famotidine was 35.7%, compared to an incidence of 75.5% in the 325 patients treated with placebo (p<0.01).

Gastric Ulcer

In both a U.S. and an international multicenter, double-blind study in patients with endoscopically confirmed active benign gastric ulcer, orally administered famotidine, 40 mg h.s., was compared to placebo h.s. Antacids were permitted during the studies, but consumption was not significantly different between the famotidine and placebo groups. As shown in Table 2, the incidence of ulcer healing (dropouts counted as unhealed) with famotidine was statistically significantly better than placebo at weeks 6 and 8 in the U.S. study, and at weeks 4, 6 and 8 in the international study, based on the number of ulcers that healed, confirmed by endoscopy.

Time to complete relief of daytime and nighttime pain was statistically significantly shorter for patients receiving famotidine than for patients receiving placebo; however, in neither study was there a statistically significant difference in the proportion of patients whose pain was relieved by the end of the study (week 8).
A medical data acquisition processing platform and method of operation for use in capturing medical data relating to one or more medical events. The processing platform including a processing system having a plurality of defined interface elements for acquiring medical data. Each of the defined interface elements provides one of data entry and selection options relative to the medical data. The processing system is further configured to provide over a network, a configurable interface to permit users to define new interface elements relating to a medical event not included in the one or more medical events. The processing platform includes an interface system to make the new interface elements available over the network to and to receive data entered by users using the defined interface elements and the new interface elements. The processing system being configured to process the data to obtain information related to the subject medical event.
In recent years there has been significant progress towards more effective and practical thromboprophylaxis in joint replacement surgeries. Since Aspirin 325mg twice daily has been recently included as a nationally approved venous thromboembolism (VTE) prophylaxis in the Surgical Care Improvement Project (SCIP) protocols for low risk total knee arthroplasty (TKA) patients, it is necessary to optimize multimodal prophylaxis methods. These include reduced tourniquet time, early mobilization, and mechanical compression devices (MCDs). MCDs are commonly used as part of the in-hospital VTE prophylaxis measures; however, it has not been demonstrated in clinical trials that optimal prophylaxis methods would be enhanced by prolonged use of a MCD after discharge. In order to achieve this, a potentially valuable solution has recently been made available to the outpatient population. The Cothera VPulse(tm) is a MCD that combines rapid intermittent sequential compression with cold therapy. It is designed for single patient use in the home and includes technology to track patient compliance. The purpose of this study is to examine if there is a difference in DVT occurrence over 3 weeks after tourniquet-less TKA and multimodal prophylaxis with or without extended MCD use in a cooling device/MCD system.